Literature DB >> 8962196

Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.

R A Williamson1, C M Yea, P A Robson, A P Curnock, S Gadher, A B Hambleton, K Woodward, J M Bruneau, P Hambleton, S Spinella-Jaegle, P Morand, O Courtin, C Sautés, R Westwood, T Hercend, E A Kuo, E Ruuth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8962196

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  10 in total

Review 1.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 2.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  Control of hyperglycemia in male mice by leflunomide: mechanisms of action.

Authors:  Junhong Chen; Jing Sun; Michelle E Doscas; Jin Ye; Ashley J Williamson; Yanchun Li; Yi Li; Richard A Prinz; Xiulong Xu
Journal:  J Endocrinol       Date:  2018-04       Impact factor: 4.286

4.  Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1.

Authors:  Issam Ben-Sahra; Jessica J Howell; John M Asara; Brendan D Manning
Journal:  Science       Date:  2013-02-21       Impact factor: 47.728

5.  Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients.

Authors:  Nicolae Leca; Kimberly A Muczynski; Jonathan A Jefferson; Ian H de Boer; Jolanta Kowalewska; Elizabeth A Kendrick; Raimund Pichler; Connie L Davis
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-27       Impact factor: 8.237

6.  3D-QSAR studies on a series of dihydroorotate dehydrogenase inhibitors: analogues of the active metabolite of leflunomide.

Authors:  Shun-Lai Li; Mao-Yu He; Hong-Guang Du
Journal:  Int J Mol Sci       Date:  2011-05-10       Impact factor: 5.923

7.  Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.

Authors:  Michelle E Doscas; Ashley J Williamson; Lydia Usha; Yedida Bogachkov; Geetha S Rao; Fei Xiao; Yimin Wang; Carl Ruby; Howard Kaufman; Jingsong Zhou; James W Williams; Yi Li; Xiulong Xu
Journal:  Neoplasia       Date:  2014-10-23       Impact factor: 5.715

8.  Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation.

Authors:  Xiulong Xu; Jing Sun; Ruilong Song; Michelle E Doscas; Ashley J Williamson; Jingsong Zhou; Jun Sun; Xinan Jiao; Xiufan Liu; Yi Li
Journal:  Oncotarget       Date:  2017-05-02

9.  Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases.

Authors:  Xiaomei Li; Jing Sun; Richard A Prinz; Xiufan Liu; Xiulong Xu
Journal:  Virology       Date:  2020-06-18       Impact factor: 3.616

10.  The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.

Authors:  Gaby Palmer; Danielle Burger; Françoise Mezin; David Magne; Cem Gabay; Jean-Michel Dayer; Pierre-André Guerne
Journal:  Arthritis Res Ther       Date:  2004-02-19       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.